2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab plus axitinib for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.
Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Aveo Oncology, Sumanta K. Pal, MD, FASCO, a professor in the Department of Medical Oncology & Therapeutics Research and codirector of the kidney cancer program at City of Hope, walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab (Bavencio) plus axitinib (Inlyta) for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma (RCC).
TIVO-3 compared tivozanib (Fotivda) vs sorafenib (Nexavar) for patients with advanced RCC who have received at least 2 prior systemic therapies. It is one of the few trials to analyze patients in the refractory setting.
Pal, a coauthor on TIVO-3, said that the odds of experiencing long-term progression-free survival (PFS) was 5 times greater for patients randomized to tivozanib. At 3 years, long-term PFS rates were 12.3% (95% CI, 8%-18%) for tivozanib vs 2.4% (95% CI, 1%-6%) with sorafenib. Tivozanib remained superior to sorafenib at 4 years, with PFS rates of 7.6% (95% CI, 4%-13%) and 0%, respectively.
Pal added that the data at 3 and 4 years was “incredibly impressive” and unexpected in refractory patients. Tivozanib, he said, should be considered for third-line therapy and added it is reasonable to consider the VEGF TKI in the second-line setting for some patients.
Pal went on to say he is excited about the possibility of neoadjuvant therapy in RCC. He was particularly intrigued by data from the NeoAvAx trial presented Axel Bex, MD, PhD. In that open-label, single-arm phase 2 trial, neoadjuvant avelumab/axitinib induced a partial response in 30% of patients (n = 12 of 40). Median primary tumor downsizing was 20% (range, +3.8% to 43.5%). Ten of the responding patients remained disease free at the data cutoff.
The field of RCC, he said, could be headed to even more aggressive therapy as investigators explore triplet combinations. Pal added that it will be important to consider quality of life when making treatment decisions and conducting clinical trials.
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Aveo Oncology. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.